Van ECK Associates Corp Has $3.31 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Van ECK Associates Corp reduced its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 5.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 72,830 shares of the company’s stock after selling 3,933 shares during the quarter. Van ECK Associates Corp’s holdings in CRISPR Therapeutics were worth $3,305,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its holdings in CRISPR Therapeutics by 172.3% during the 2nd quarter. Geneos Wealth Management Inc. now owns 561 shares of the company’s stock worth $31,000 after purchasing an additional 355 shares in the last quarter. CWM LLC grew its holdings in shares of CRISPR Therapeutics by 80.7% in the third quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares in the last quarter. Tradewinds Capital Management LLC grew its holdings in shares of CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock valued at $32,000 after acquiring an additional 600 shares in the last quarter. Pinnacle Holdings LLC bought a new position in CRISPR Therapeutics during the first quarter valued at $48,000. Finally, Spire Wealth Management grew its holdings in CRISPR Therapeutics by 101.8% during the second quarter. Spire Wealth Management now owns 793 shares of the company’s stock valued at $45,000 after purchasing an additional 400 shares during the period. 68.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the transaction, the chief executive officer now directly owns 187,377 shares in the company, valued at approximately $11,711,062.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CRSP shares. Mizuho restated a “buy” rating and set a $82.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 8th. Truist Financial reiterated a “buy” rating on shares of CRISPR Therapeutics in a research report on Friday, December 8th. Morgan Stanley lowered their price target on CRISPR Therapeutics from $43.00 to $42.00 and set an “underweight” rating on the stock in a research report on Monday, November 13th. Needham & Company LLC raised their price target on CRISPR Therapeutics from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Monday, December 11th. Finally, TD Cowen downgraded CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $68.39.

Check Out Our Latest Analysis on CRSP

CRISPR Therapeutics Stock Performance

CRSP stock opened at $76.44 on Tuesday. The firm has a 50 day moving average price of $64.24 and a 200-day moving average price of $55.49. CRISPR Therapeutics AG has a 52-week low of $37.55 and a 52-week high of $76.97. The firm has a market capitalization of $6.07 billion, a price-to-earnings ratio of -17.10 and a beta of 1.73.

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPFree Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.